Fujifilm Kyowa Kirin Biologics Co., Ltd.
Quick facts
Phase 3 pipeline
- FKB327 · Oncology
FKB327 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T-cell responses.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: